The diagnosis of thrombocytopenia in newborns and infants is relatively difficult and it should be diagnosis by exclusion. The most important causes of thrombocytopenia that need to be considered in this group are infections, including sepsis as well as CMV infection, fetal hypoxia, chromosomal abnormalities, bone marrow proliferative diseases and neonatal immune thrombocytopenia.

A rare cause of infant thrombocytopenia is genetically determined, most often X-linked, primary immunodeficiency – Wiskott-Aldrich syndrome (WAS).

Depending on the type of mutation in the WAS gene, encoding the WAS protein, there is a wide spectrum of clinical phenotypes: X-linked thrombocytopenia, X-linked neutropenia and classic WAS. The last one is characterized by a triad of symptoms: thrombocytopenia, usually with small platelets, recurrent infections, and eczema.

This case – report presents the case of a 4-month-old boy with thrombocytopenia resistant to treatment found from the second day of his life, who was diagnosed with full-blown Wiskott – Aldrich syndrome in the following weeks. An additional difficulty in the differential diagnosis in this case was the boy’s negative family history and the normal size of the platelets in the tests, which is atypical for WAS. The diagnosis was confirmed by a molecular test which revealed a new mutation, not registered in the ClinVar and HGMD database.

The boy’s severe course of disease has been brought under control thanks to a bone marrow transplant from his mother in the age of 12 months.

Hemophilia A is characterized by deficiency in FVIII and approximately 30% of people with severe hemophilia A are affected by inhibitors.

A 11-year-old boy was diagnosed with severe hemophilia A immediately after birth due to hematoma around right kidney and positive family history. He developed inhibitors on FVIII when he was 12 months of age and therapy was changed in activated prothrombin complex on demand. During next 9 years, recurrent bleeding in the both knees started to occur which was manifested with haemophiliac arthropathy.

After several attempt, immune tolerance induction (ITI) was approved by insurance company when he was 10 years old. We started with plasma-derived F VIII in dosage of 100 i.u. per kg BW daily. Titer of inhibitors was negative after 3 months of ITI, and half life of FVIII was normalised after 6 months.

For ease of administering therapy, central venous catheter (CVC) was inserted in right subclavian vein. On the other hand, usage of CVC can be complicated by infections and thrombosis. Year one after insertion of CVC, he became febrile and microbiology findings revealed that blood culture was contaminated with Staphylococcus aureus, Acinetobacter ursingii, Achromobacter xyloxidans and Fusarium proliferatum which was indication for emergency removal of CVC. Unfortunately, during that surgical intervention, breakage of a CVC occurred and the tip of the catheter was notably missing.

Emergency MSCT of thorax showed tubular structure located in right ventricle with loop at the entrance of right atrium and descending into the inferior vena cava as well as confluence with hepatic veins. To avoid major surgery, the retained portion was successfully removed by the interventional cardiologist through a femoral vein. During procedure, patient received plasma-derived FVIII to maintain the value of FVIII above 80% and there was no bleeding. Prophylactic antibiotics (meropenem, teicoplanin, liposomal amphotericin B) were continued for 10 days. After three negative blood cultures, negative galactomannan (GM) and 1,3-β-d-glucan (BDG) tests, he was released home and regularly controlled in day hospital. He is now using plasma-derived F VIII 1500 IU every other day as a prophylaxis of hemophilia A and is doing well without bleeding and development of inhibitors.